arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Neuronetics, Inc.

STIM
$2.38 ▲ +0.12 (+5.09%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
11 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neuronetics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $157.0M
Dividend Yield
Revenue Growth 99.2%
Op. Margin -21.1%
ROIC -28.2%
FCF / Share $-0.31
Trailing P/E
Price / Book 7.3x
FCF Yield
Debt / Equity 2.94
info Valuation on last close. End-of-day price, Aug 7, 2026.

11-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$149.16M
↑ +99.2%
Net Income Profit after all expenses
$-39.00M
↑ +10.8%
Operating Margin Operating profit as % of sales
-21.1%
↑ +54.3% 10th
FCF / Share Free cash flow per share
$-0.31
↑ +68.4%
Long-Term Debt Long-term obligations
$65.81M
↑ +19.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
4
Financial Health
23
Cash Quality
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 39 quarters